In a day or two the clinic of the Research Institute of Hematology and Blood Transfusion will open its onco-hematology unit. It is worth noting the clinic does not stop for a minute the work to improve the quality of care of these patients.
Specialists on a regular basis update the national register of children with leukemia and thalassemia. It is important for the timely provision of children with free drugs to perform modern and highly-efficient therapy. For their purchase this year the state budget has allocated 856 million soums.
To date, this is the key factor to achieve the objectives to improve the treatment of these patients. Doctors aim to achieve a reduction in children with leukemia mortality by 50 per cent, improving the quality of life and increasing rates of 5-year survival rate from 40 to 90 per cent. Reducing the mortality of children with thalassemia should reach 70 per cent, improvement in quality of life, increasing the performance of 25-year survival rate from 10 per cent to 90 per cent.
Specialists of the Research Institute receive help from the Swiss pharmaceutical company Novartis. The company has allocated $18mln for the organization of monitoring of treatment with the identification of ferritin in the blood of patients with thalassemia and scientific analysis of the effectiveness of treatment.
In addition, the company allocated $65 thousand to the training program. Hematologists improve their skills and knowledge in the field of chelator therapy. A school of thalassemia is opened for parents, in which they learn how to care for a sick child.